

osimertinib (TAGRISSO)

Diagnosis Considered for Coverage:

- Non-small cell lung cancer (NSCLC)
- Leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer

Coverage Criteria:

**For diagnosis of non-small cell lung cancer (NSCLC):**

1. Presence of one of the following EGFR mutations
  - a. Exon 19 deletion, or
  - b. Exon 21 L858R mutation, or
  - c. T790M mutation, or
  - d. S768I mutation, or
  - e. L861Q mutation, or
  - f. G719X mutation
- and
2. One of the following:
  - a. Being used as a single agent, or
  - b. Being used in combination with pemetrexed and either carboplatin or cisplatin
- and
3. Dose does not exceed 80 mg per day

**For diagnosis of Leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer:**

1. Presence of the EGFR gene mutation, and
2. Dose does not exceed 160 mg per day.

**Coverage Duration:** one year

Effective Date: 02/28/2024